Rigel Pharmaceuticals, Inc. - Common Stock (RIGL)

Rigel Pharmaceuticals (RIGL) is a biotech stock with a compelling valuation, trading at a low P/E ratio. It boasts strong profitability, exceptional revenue & EPS growth, and solid financial health.

Rigel Pharmaceuticals shows explosive growth with 729% EPS growth, 106% revenue surge, and a 119% ROE, making it a top pick for momentum investors.

Discover RIGL stock's high growth momentum & strong technical setup. A top pick for investors seeking earnings acceleration & breakout potential.

Rigel Pharmaceuticals (RIGL) is a GARP stock with explosive 729% EPS growth, trading at a deep discount with a P/E of just 7.11.

Rigel Pharmaceuticals (RIGL) presents a strong value investing case with a high valuation score, robust profitability, and impressive revenue growth, trading below intrinsic value.

Rigel Pharmaceuticals (RIGL) excels in a proven growth stock screening method, showing massive earnings growth, soaring revenue, and a high return on equity.

Additionally, the IBD SmartSelect Composite Rating for Argenx stock rose from 94 to a near best 96 Tuesday.

Unusual volume stocks are being observed in Tuesday's session.

Let's have a look at what is happening on the US markets on Monday. Below you can find the stocks with an unusual volume in today's session.

Louis Navellier’s growth investing strategy highlights stocks like RIGL with strong earnings momentum, rising sales, and profitability, making it a standout pick for investors.

The three major indices were mostly flat in midday trading Wednesday with the S&P 500 and Nasdaq slightly under the flatline and the Dow Jones up 39 points. 

U.S. stocks plunged Tuesday as President Donald Trump‘s tariffs on key trade partners came into effect, prompting retaliatory measures and intensifying global trade tensions.

The intense retail focus on Anavex reflects a broader market interest in neurodegenerative therapies, especially following disappointing trial results from Cassava Sciences’ simufilam.